Table 2 Subgroup analysis of the risk of fracture
From: Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Subgroup | No. of included studies | RR (95% CI) | I2 (%) |
|---|---|---|---|
Comparator treatment | |||
Alendronate | 3 | 1.10 (0.95, 1.23) | 12.3 |
Ibandronate | 1 | 1.08 (0.89, 1.16) | – |
Risedronate | 1 | 1.23 (0.75, 1.08) | – |
Zoledronic acid | 1 | 0.86 (0.74, 0.99) | – |
Population who had been prescribed a treatment for osteoporosis | |||
No (< 100% of participants) | 4 | 1.15 (0.67, 1.22) | 0.0 |
No (> 100% of participants) | 3 | 1.12 (0.85, 1.08) | 0.0 |
High or unclear risk of bias | |||
No | 2 | 1.09 (0.74, 1.26) | 0.0 |
Yes | 5 | 1.31 (0.89, 1.14) | 0.0 |